Kiley Juergens Wealth Management LLC Sells 6,077 Shares of Pfizer Inc. (NYSE:PFE)

Kiley Juergens Wealth Management LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 24.8% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 18,429 shares of the biopharmaceutical company’s stock after selling 6,077 shares during the period. Kiley Juergens Wealth Management LLC’s holdings in Pfizer were worth $531,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the stock. Tyche Wealth Partners LLC bought a new position in Pfizer during the 4th quarter worth $618,000. HealthInvest Partners AB acquired a new stake in Pfizer during the 4th quarter worth about $1,233,000. Allen Capital Group LLC grew its holdings in Pfizer by 59.4% during the 4th quarter. Allen Capital Group LLC now owns 107,758 shares of the biopharmaceutical company’s stock worth $3,102,000 after acquiring an additional 40,145 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Pfizer by 4.0% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,777,606 shares of the biopharmaceutical company’s stock worth $79,967,000 after acquiring an additional 106,682 shares during the period. Finally, Signet Financial Management LLC grew its holdings in Pfizer by 4.3% during the 4th quarter. Signet Financial Management LLC now owns 41,591 shares of the biopharmaceutical company’s stock worth $1,197,000 after acquiring an additional 1,730 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Performance

Shares of Pfizer stock traded down $0.22 during mid-day trading on Tuesday, hitting $25.69. 28,601,821 shares of the stock were exchanged, compared to its average volume of 42,553,457. Pfizer Inc. has a 12 month low of $25.61 and a 12 month high of $41.33. The company has a 50-day simple moving average of $27.27 and a 200 day simple moving average of $28.84. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The company has a market capitalization of $145.47 billion, a P/E ratio of 71.69, a P/E/G ratio of 1.16 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same quarter last year, the firm earned $1.14 EPS. The company’s quarterly revenue was down 41.3% compared to the same quarter last year. Sell-side analysts anticipate that Pfizer Inc. will post 2.22 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on PFE shares. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a report on Thursday, January 4th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research note on Monday. Guggenheim started coverage on Pfizer in a research note on Friday, February 23rd. They issued a “buy” rating and a $36.00 target price for the company. Finally, Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Twelve analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of “Hold” and a consensus target price of $36.88.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.